MedTrace Logo

Ascorbic Acid Treatment in CMT1A Trial (AATIC)

NCT00271635 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2008-07-04

No results posted yet for this study

Summary

Charcot-Marie-Tooth type IA (CMT1A) is the most prevalent hereditary peripheral neuropathy. Demyelination of peripheral nerves is the hallmark of CMT1A. Ascorbic acid has been shown to have a favorable influence on myelination in in vitro studies and in a mouse model for CMT1A. We will study the efficacy and safety of ascorbic acid treatment in young patients with CMT1A.

Conditions

  • Charcot-Marie-Tooth Disease
  • Hereditary Motor and Sensory Neuropathies

Interventions

DRUG

Placebo

Placebo 4 capsules b.i.d. during 1 year

DRUG

ascorbic acid

Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • C. Verhamme, MD · Department of Neurology, Academic Medical Center, University of Amsterdam

  • M. Vermeulen, MD, PhD · Department of Neurology, Academic Medical Center, University of Amsterdam

  • F. Baas, MD, PhD · Department of Neurology, Academic Medical Center, University of Amsterdam

  • R. de Haan, MD, PhD · Department of Neurology, Academic Medical Center, University of Amsterdam

  • M. de Visser, MD, PhD · Department of Neurology, Academic Medical Center, University of Amsterdam

  • I. N van Schaik, MD, PhD · Department of Neurology, Academic Medical Center, University of Amsterdam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00271635 on ClinicalTrials.gov